The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125351261 12535126 1 I 20160622 20160707 20160707 EXP US-CIPLA LTD.-2016US08455 CIPLA EL-KHOUEIRY AB, RAMANATHAN RK, YANG DY, ZHANG W, SHIBATA S, WRIGHT JJ ET AL.,. A RANDOMIZED PHASE II OF GEMCITABINE AND SORAFENIB VERSUS SORAFENIB ALONE IN PATIENTS WITH METASTATIC PANCREATIC CANCER. INVEST NEW DRUGS. 2012;30:1175 TO 1183 0.00 Y 0.00000 20160707 CN US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125351261 12535126 1 PS GEMCITABINE GEMCITABINEGEMCITABINE HYDROCHLORIDE 1 Intravenous (not otherwise specified) 1000 MG/M2, AT A RATE OF 10 MG/M2/MIN, WEEKLY FOR 3 OUT OF 4 WEEKS 78759 1000 MG/M**2
125351261 12535126 2 SS Sorafenib SORAFENIB 1 Oral 200 MG, BID, TWO TABLETS 0 200 MG TABLET

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125351261 12535126 1 Pancreatic carcinoma metastatic
125351261 12535126 2 Pancreatic carcinoma metastatic

Outcome of event

Event ID CASEID OUTC COD
125351261 12535126 DE

Reactions reported

Event ID CASEID DRUG REC ACT PT
125351261 12535126 Disease progression

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found